Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Australia Needs Stronger Leadership For Biotech To Prosper

Executive Summary

As Australia ends a resources boom, a decline in manufacturing has left the country vulnerable, and a concerted investment in biotechnology could transform the country, according to a new report.

You may also be interested in...

Novartis adds novel pain program via $200m Spinifex buy

Executing on its planned strategy for an 'exit' exactly on schedule, Australian/US biotech Spinifex Pharmaceuticals has agreed to be acquired by Novartis for $200m plus undisclosed development and regulatory milestones.

Stock Watch: Alnylam’s Date With The Competition

When a loss-making rare disease biotech company’s product takes on Pfizer in the same indication but without the benefit of superior data, pharmaceutical marketing lessons will be learnt.

Dutch Firm TheOTCLab Gets EU MDR Approval For Dr. Yglo OTC Wart Device

Amsterdam-based TheOTCLab has received an EU CE mark for its new wart and verruca OTC freezing device Dr. Yglo. The firm plans to launch the product in Europe in Italy, Portugal, Estonia, Latvia, and Lithuania, and will separately look to take it further afield to the US and South Africa.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts